Basalt Health Raises $20M Series A Led by NEA

Basalt Health has raised a $20M Series A to speed the referral decisions that move patients from hospitals into post-acute care. Returning investor NEA led the financing, with existing investors Frist Cressey Ventures and 25m Health participating.

The Nashville company says the round brings its total capital raised to approximately $24.5M. Basalt will use the money to expand from admissions into discharge and payer workflows while hiring across engineering, implementation, sales, and marketing.

The market implication is unusually practical. Healthcare AI does not have to replace a clinician to change capacity; it can make the evidence behind a placement decision arrive before the bed, patient, and referral source move on.

What Happened

Basalt's September 24 announcement describes a $20M Series A led by NEA, which first invested in the company in 2025. Frist Cressey Ventures and 25m Health also returned for the round, while Basalt reported no valuation and did not separately disclose the size of its prior seed financing.

Founder and CEO Ben Hackett started Basalt in 2024 after nearly a decade at Accolade. The company now focuses on post-acute admissions, where hospitals, skilled-nursing facilities, inpatient rehabilitation centers, long-term acute-care hospitals, and behavioral-health providers must move clinical records and make placement decisions across organizations that rarely share one clean workflow.

That workflow still carries a surprising amount of fax paper. Basalt says roughly 14M patients enter post-acute care each year and that a typical placement sends a packet to 6.6 facilities, figures the company uses to frame a market where delay can strand a patient in an acute-care bed while the receiving facility is still reading.

How Basalt Handles the Referral

Basalt's post-acute admissions product ingests a referral from fax, portal, or direct integration and reads the clinical packet as it arrives. It checks the extracted information against a facility's own clinical and payer criteria, then surfaces red, yellow, or green findings with links back to the source document.

That source trail matters. Basalt says the system prepares the decision rather than making it, which keeps the clinician responsible for the admission while reducing the chart work required to understand diagnoses, medications, functional status, coverage, and facility-specific risks.

The same cited evidence can continue into prior authorization, continued-stay review, and appeals. Basalt's public security and compliance description says customer data is encrypted in transit and at rest, access is logged and limited by role, minimum-necessary PHI is displayed, and the company signs a business associate agreement with every customer.

The Customer Evidence Behind the Round

Basalt reports that its deployment at Lifepoint Health reduced median chart-processing time from 8.5 minutes to 1.2 minutes, an 86% decrease. The company says it has been live with Lifepoint since its 2025 seed round and plans implementation across 49 additional Lifepoint markets by the end of 2026.

At ScionHealth, Basalt says the platform is scaling to 62 hospitals by year-end and would manage incoming referrals across a network of more than 6,000 practitioners. Those performance and deployment figures come from the company announcement, so they establish reported operating traction rather than independently audited outcomes.

Independent reporting supports the transaction and the category interest. Axios Pro confirmed the $20M Series A and described growing investor and strategic attention around post-acute administrative workflows.

Why This Matters for Healthcare AI

Healthcare software often asks clinicians to abandon an old workflow before proving the new one can survive real operations. Basalt is taking the opposite route by meeting the fax, scanned document, and fragmented referral where they already exist, then trying to make the review faster and more consistent without hiding the evidence.

That approach fits the incentives inside post-acute care. A receiving facility needs to know whether it can safely serve the patient, the hospital needs a timely discharge, the payer needs documented medical necessity, and the patient needs the handoff to happen before another option disappears. A faster answer creates value only when the people making the decision can defend it.

The Series A therefore finances more than document extraction. It backs a workflow in which AI must read messy records, respect local criteria, connect clinical and payer logic, and earn trust from the staff who remain accountable when a placement succeeds or fails.

What the Series A Changes

Basalt plans to extend its product from admissions into discharge and payer workflows. That expansion would place the same evidence layer across more of the transition, from determining whether a facility can accept a patient to documenting authorization and supporting an appeal when coverage is denied.

The company is also hiring across implementation, engineering, sales, and marketing. Enterprise healthcare growth will make those functions as consequential as the model itself because every new system brings integration work, local criteria, security review, procurement, training, and the obligation to support a live clinical operation.

Basalt's next phase will be measured in those handoffs. The company has to turn reported time savings at early health-system partners into repeatable deployment across more markets while preserving the source visibility and human authority that made the product acceptable in the first place.